Bone Metastases from Prostate Cancer (eBook)

Biology, Diagnosis and Management
eBook Download: PDF
2016 | 1st ed. 2017
X, 293 Seiten
Springer International Publishing (Verlag)
978-3-319-42327-2 (ISBN)

Lese- und Medienproben

Bone Metastases from Prostate Cancer -
Systemvoraussetzungen
96,29 inkl. MwSt
  • Download sofort lieferbar
  • Zahlungsarten anzeigen

This book presents up-to-date information on one of the hottest topics in prostate cancer, namely bone metastases. The most recent developments with respect to biology, pathology, diagnosis, and treatment are described, providing readers with an excellent understanding of the mechanisms of metastasis formation, the characteristics of metastases, their aggressiveness, and prognostic factors for treatment response. The coverage includes discussion of all of the best available options (laboratory, radiology, and nuclear medicine) for achieving early diagnosis and both established and novel therapeutic approaches. Detailed information is provided on hormonal manipulations, bone-targeted agents, vaccines, taxanes, and other treatments that are enriching the therapeutic armamentarium. The editors can be considered leaders in the field, with great experience in diagnostic and clinical oncology and research, and the authors are experts in diverse specialties. This ensures a multidisciplinary approach, mirroring the current situation in which treatment in patients with bone metastases is undertaken by a team of specialists and health professionals in a variety of fields.



Francesco Bertoldo, MD, is Associate Professor of Internal Medicine at the School of Medicine, University of Verona, Italy. Since 2003 he has been Chief of Bone and Mineral Metabolism Diseases and the Osteo-oncology Unit in the Department of Medicine, University Hospital GB Rossi, Verona, Italy. Dr. Bertoldo is a member of the Directive Council of the Italian Society of Osteoporosis and Bone Diseases (SIOMMMS) and of the Italian Society of Osteo-oncology. Since 2009 he has been a member of the Guidelines Committee of the Italian Association of Medical Oncology (AIOM) and SIOMMMS. In 2011 he served as coordinator of the Guidelines for Bone Disease in Prostate Cancer produced by the Italian Society of Urology. He has published more than 100 papers in national and international journals in the field of metabolic and cancer-related bone diseases.

Francesco Boccardo graduated cum laude in 1975 from the Medical School of the University of Genoa, Italy, where he then specialized in Oncology. He started his professional career in 1977 at the National Cancer Institute in Genoa and is now Director of the Academic Unit of Medical Oncology at the Institute. In 1998 he was appointed Full Professor of Medical Oncology at the Medical School of the University of Genoa, Italy, where, since 2001 he has been Director of the Postgraduate Medical School in Medical Oncology. Dr. Boccardo has served as President of the Italian Association of Medical Oncology (AIOM) and was one of the founders of the Italian Society of Urologic Oncology (SIURO).

Emilio Bombardieri, MD, is a specialist in Nuclear Medicine, Oncology, and Sports Medicine who is currently Clinical Scientific Director of Nuclear Medicine at the Humanitas Gavazzeni Hospital, Bergamo, Italy. In a long career he became Director of the Nuclear Medicine Division of the Istituto Nazionale Tumori, Milan in 1994 and Director of the Department of Diagnostic Imaging and Radiotherapy at the Institute in 2007. Since 1982 he has been Professor of Physiology and Endocrinology at the Catholic University, ISEF, Milan. Dr. Bombardieri has served as President of the Italian Association of Nuclear Medicine (AIMN), has chaired the EANM (European Association of Nuclear Medicine) Oncology Committee, and was nominated President of the EANM Congress 2012 in Milan. He has published more than 400 papers in national and international journals, and several scientific textbooks in Diagnostic Imaging and Oncology.

Laura Evangelista, MD, PhD, is a nuclear medicine physician at Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. Following a residency in Nuclear Medicine at University 'Federico II' of Napoli, Italy, she worked as a research fellow at the University 'Federico II' of Napoli, the Memorial Sloan Kettering Hospital, New York City, and the Mayo Clinic of Rochester, USA, focusing on PET/CT in breast cancer, prostate cancer, and other oncological diseases. She is a member of the Translational and Molecular Imaging Committee for the European Association of Nuclear Medicine. She has published about 100 papers in national and international journals in the field of nuclear medicine.


Riccardo Valdagni has been Head of the Oncologic Radiotherapy Unit at the National Cancer Institute in Milan since 2011 and Head of the Prostate Program since 2003. Since 2009 he has been Vice President of the Italian Society of Oncologic Urology (SIUrO) and in 2010 he became a member of the Steering Committee of the multicenter international active surveillance protocol PRIAS (Prostate Cancer Research International: Active Surveillance). Dr. Valdagni is dedicated to the development of an integrated and multidisciplinary approach to prostate cancer. He has always been interested in psychology and psycho-oncology, and is a professor at the Il Ruolo Terapeutico psychoanalytic therapy center. He is the author of many international scientific publications in the field of Oncology. 


 

 

Francesco Bertoldo, MD, is Associate Professor of Internal Medicine at the School of Medicine, University of Verona, Italy. Since 2003 he has been Chief of Bone and Mineral Metabolism Diseases and the Osteo-oncology Unit in the Department of Medicine, University Hospital GB Rossi, Verona, Italy. Dr. Bertoldo is a member of the Directive Council of the Italian Society of Osteoporosis and Bone Diseases (SIOMMMS) and of the Italian Society of Osteo-oncology. Since 2009 he has been a member of the Guidelines Committee of the Italian Association of Medical Oncology (AIOM) and SIOMMMS. In 2011 he served as coordinator of the Guidelines for Bone Disease in Prostate Cancer produced by the Italian Society of Urology. He has published more than 100 papers in national and international journals in the field of metabolic and cancer-related bone diseases.Francesco Boccardo graduated cum laude in 1975 from the Medical School of the University of Genoa, Italy, where he then specialized in Oncology. He started his professional career in 1977 at the National Cancer Institute in Genoa and is now Director of the Academic Unit of Medical Oncology at the Institute. In 1998 he was appointed Full Professor of Medical Oncology at the Medical School of the University of Genoa, Italy, where, since 2001 he has been Director of the Postgraduate Medical School in Medical Oncology. Dr. Boccardo has served as President of the Italian Association of Medical Oncology (AIOM) and was one of the founders of the Italian Society of Urologic Oncology (SIURO).Emilio Bombardieri, MD, is a specialist in Nuclear Medicine, Oncology, and Sports Medicine who is currently Clinical Scientific Director of Nuclear Medicine at the Humanitas Gavazzeni Hospital, Bergamo, Italy. In a long career he became Director of the Nuclear Medicine Division of the Istituto Nazionale Tumori, Milan in 1994 and Director of the Department of Diagnostic Imaging and Radiotherapy at the Institute in 2007. Since 1982 he has been Professor of Physiology and Endocrinology at the Catholic University, ISEF, Milan. Dr. Bombardieri has served as President of the Italian Association of Nuclear Medicine (AIMN), has chaired the EANM (European Association of Nuclear Medicine) Oncology Committee, and was nominated President of the EANM Congress 2012 in Milan. He has published more than 400 papers in national and international journals, and several scientific textbooks in Diagnostic Imaging and Oncology.Laura Evangelista, MD, PhD, is a nuclear medicine physician at Veneto Institute of Oncology IOV – IRCCS, Padua, Italy. Following a residency in Nuclear Medicine at University “Federico II” of Napoli, Italy, she worked as a research fellow at the University “Federico II” of Napoli, the Memorial Sloan Kettering Hospital, New York City, and the Mayo Clinic of Rochester, USA, focusing on PET/CT in breast cancer, prostate cancer, and other oncological diseases. She is a member of the Translational and Molecular Imaging Committee for the European Association of Nuclear Medicine. She has published about 100 papers in national and international journals in the field of nuclear medicine.Riccardo Valdagni has been Head of the Oncologic Radiotherapy Unit at the National Cancer Institute in Milan since 2011 and Head of the Prostate Program since 2003. Since 2009 he has been Vice President of the Italian Society of Oncologic Urology (SIUrO) and in 2010 he became a member of the Steering Committee of the multicenter international active surveillance protocol PRIAS (Prostate Cancer Research International: Active Surveillance). Dr. Valdagni is dedicated to the development of an integrated and multidisciplinary approach to prostate cancer. He has always been interested in psychology and psycho-oncology, and is a professor at the Il Ruolo Terapeutico psychoanalytic therapy center. He is the author of many international scientific publications in the field of Oncology.     

Biology and pathophysiology of bone metastases.- Markers of bone turnover.- Bone homing and metastasis.- Markers of prostate cancer.- Circulating cells.- Radiological assessment of bone metastases.- Nuclear Medicine: bone target imaging.- Nuclear Medicine: cancer and receptor target imaging.- Hormonal therapy.- Chemotherapy .- Combinations of hormonal therapy and chemotherapy.- Surgery.- Radiotherapy.- Bone-targeted agents.- Bone seeking radionuclide for therapy.- New frontiers in treatments.- Approaches for the assessment of response to therapies.- From Symptom control to pain palliation.- Economic impact of prostate cancer bone metastases.- Multidisciplinary approach. 

Erscheint lt. Verlag 7.11.2016
Zusatzinfo X, 293 p. 63 illus., 40 illus. in color.
Verlagsort Cham
Sprache englisch
Themenwelt Medizin / Pharmazie Allgemeines / Lexika
Medizin / Pharmazie Medizinische Fachgebiete Orthopädie
Medizinische Fachgebiete Radiologie / Bildgebende Verfahren Radiologie
Medizin / Pharmazie Medizinische Fachgebiete Urologie
Schlagworte Bone-seeking radionuclides • Bone-targeted agents • Circulating cells • Combined hormonal therapy and chemotherapy • Formation of bone metastases • Hormonal therapy • Markers of prostate cancer • Nuclear medicine techniques • Radiaton Oncology • Radiotherapy for bone metastases
ISBN-10 3-319-42327-4 / 3319423274
ISBN-13 978-3-319-42327-2 / 9783319423272
Haben Sie eine Frage zum Produkt?
PDFPDF (Wasserzeichen)
Größe: 15,6 MB

DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasser­zeichen und ist damit für Sie persona­lisiert. Bei einer missbräuch­lichen Weiter­gabe des eBooks an Dritte ist eine Rück­ver­folgung an die Quelle möglich.

Dateiformat: PDF (Portable Document Format)
Mit einem festen Seiten­layout eignet sich die PDF besonders für Fach­bücher mit Spalten, Tabellen und Abbild­ungen. Eine PDF kann auf fast allen Geräten ange­zeigt werden, ist aber für kleine Displays (Smart­phone, eReader) nur einge­schränkt geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich